Moteur de recherche d’entreprises européennes
Financement de l’UE (89,8 M €) : ACCÉLÉRATEUR EUROPÉEN DE RÉGIME POUR LA TUBERCULOSE Hor01/01/2020 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
ACCÉLÉRATEUR EUROPÉEN DE RÉGIME POUR LA TUBERCULOSE
The European Regimen Accelerator for Tuberculosis (ERA4TB) has the explicit goal of developing a new combination therapy to treat all forms of TB starting from ~20 leads and drug candidates provided by EFPIA. Since details of these are as yet unavailable, we will implement an agile drug development algorithm that entails profiling and portfolio construction. Profiling involves characterisation and ranking molecules in preclinical studies comprising in vitro drug combination assays, hollow fiber and single cell analysis, innovative murine and non-human primate models, PK/PD studies, combined with biomarker discovery and non-invasive NIR or PET/CT imaging to monitor disease progression and response to treatment. Modelling, simulation and artificial intelligence tools will help progress compounds from early preclinical to clinical development and to predict drug exposure, human doses and the best combinations. After extensive preclinical profiling, selected compounds will enter portfolio development for first time in human tests and phase I clinical trials in order to ensure that they are safe, well-tolerated and bioavailable with negligible drug-drug interactions. If needed, formulation studies will be conducted to improve pharmacological properties. ERA4TB has assembled the best expertise and resources available in Europe, to build a highly effective and sustainable drug development consortium with a flexible and dynamic management system to execute the profiling and portfolio strategy, aided by clearly defined go/no-go decision points. The expected outcome of ERA4TB is a series of highly active, bactericidal, orally available drugs to constitute two or more new combination regimens with treatment-shortening potential ready for Phase II clinical evaluation. These regimens will be compatible with drugs used to treat common comorbidities, such as HIV-AIDS and diabetes, and should impact UN Sustainable Development Goal 3, namely, ending TB by 2030.
| Aliri France SAS | 837 500 € |
| Bill & Melinda Gates Foundation | 0,00 € |
| 1 856 250 € | |
| 3 557 500 € | |
| Commissariat a L Energie Atomique et aux Energies Alternatives | 2 476 939 € |
| Consiglio Nazionale Delle Ricerche | 2 443 750 € |
| 2 282 040 € | |
| ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE | 962 500 € |
| EVOTEC INTERNATIONAL GmbH | 0,00 € |
| FONDATION INNOVATIVE MEDICINES FOR TUBERCULOSIS (IM4TB) | 22,2 M € |
| 2 287 500 € | |
| 0,00 € | |
| Glaxosmithkline Investigacion y Desarrollo SL | 0,00 € |
| Global Alliance FOR TB Drug Development NON Profit Organisation | 0,00 € |
| 1 132 500 € | |
| Institut Pasteur | 10,9 M € |
| Institut Pasteur de Lille Fondation | 2 853 750 € |
| 277 500 € | |
| Janssen Pharmaceutica N.V. | 0,00 € |
| 1 407 500 € | |
| 399 688 € | |
| Lunds Universitet | 0,00 € |
| 293 500 € | |
| QPS Netherlands B.V. | 6 175 320 € |
| Sciensano | 1 637 500 € |
| 11,1 M € | |
| Synapse Research Management Partners SL | 2 397 359 € |
| Universidad Carlos III de Madrid | 5 084 941 € |
| Universidad de Zaragoza | 4 247 900 € |
| Universita Degli Studi DI Padova | 615 000 € |
| Universita Degli Studi DI Pavia | 592 000 € |
| University of Dundee | 0,00 € |
| Uppsala Universitet | 1 797 500 € |
https://cordis.europa.eu/project/id/853989
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
Les visualisations de "Aliri France SAS - Financement de l’UE (89,8 M €) : ACCÉLÉRATEUR EUROPÉEN DE RÉGIME POUR LA TUBERCULOSE"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
